We’ve all heard the drumbeat: total hip arthroplasty (THA) is a mature, commodity market. Implants are reliable, survival curves flatline nicely out to 15–20 years for well-positioned constructs, and the big players battle over razor-thin margins on polyethylene, ceramics, and fixation tweaks.
I have written about how the smart innovation money has pivoted to the Throughput Accelerator Strategy — robotics, navigation, outpatient pathways, bundled payments, and reducing the total cost of care. The real moat, we were told, moved from the metal to the ecosystem.
But every so often, pure implant architecture reasserts itself and forces the question: Can structural engineering still create a durable clinical (and commercial) moat? Florida-based Hip Innovation Technology (HIT) and its Reverse Hip Replacement System (Reverse HRS) are the latest test case. With a multi-center FDA Investigational Device Exemption (IDE) pivotal trial (NCT05357378) actively enrolling at high-volume sites including Tampa General Hospital and Florida Orthopaedic Institute, the orthopedic world is watching closely.
Reversing the Biomechanical Equation
Let’s be precise. This is not a reverse shoulder. No deltoi...
